drugset / Trial / NCT00345189
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, dose-escalation, safety, pharmacokinetics, and pharmacodynamics study.
Timeline
- Start
- 2006-02
- Primary completion
- 2008-07
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIIB021 | Small molecule | 25 mg | Oral |
| Subject | BIIB021 | Small molecule | 600 mg | Oral |